Clinical Edge Journal Scan

Obesity may be protective against diabetic retinopathy in T2D


 

Key clinical point: Obesity appeared to be a protective factor for the development of diabetic macular edema (DME) and vision-threatening diabetic retinopathy (VTDR) in patients with type 2 diabetes mellitus (T2D), whereas the waist-to-height ratio appeared to be a significant risk factor.

Major finding: Obesity was associated with a lower risk for DME (adjusted odds ratio [aOR] 0.40; P = .041) and VTDR (aOR 0.37; P = .023), whereas a higher waist-to-height ratio was associated with a higher risk for DME (aOR 3.04; P = .041) and VTDR (aOR 2.74; P = .048), with all associations being more significant in women.

Study details: Findings are from an ongoing prospective study that included 2305 patients with T2D.

Disclosures: This study was supported by the National Natural Science Foundation of China and Guangzhou Science & Technology Plan of Guangdong Pearl River Talents Program. No competing interests were declared.

Source: Li W et al. Association of different kinds of obesity with diabetic retinopathy in patients with type 2 diabetes. BMJ Open. 2023;12:e056332 (May 19). Doi: 10.1136/bmjopen-2021-056332

Recommended Reading

Diabetes tied to risk of long COVID, too
Type 2 Diabetes ICYMI
Experts elevate new drugs for diabetic kidney disease
Type 2 Diabetes ICYMI
What’s the best time of day to exercise? It depends on your goals
Type 2 Diabetes ICYMI
Could a type 2 diabetes drug tackle kidney stones?
Type 2 Diabetes ICYMI
Once-weekly dulaglutide improves glycemic control in youths with T2D
Type 2 Diabetes ICYMI
T2D: Cardiovascular and safety outcomes associated first-line SGLT-2i vs. metformin
Type 2 Diabetes ICYMI
Metformin combination therapy tops metformin monotherapy in untreated T2D
Type 2 Diabetes ICYMI
OGTT prognostic for T2D risk in nulliparous pregnant women testing negative for GD
Type 2 Diabetes ICYMI
T2D: Meta-analysis suggests superiority of tirzepatide over other glucose lowering therapies
Type 2 Diabetes ICYMI
Insights on comparative efficacy of tirzepatide and semaglutide in T2D
Type 2 Diabetes ICYMI